Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis
Cosmo Pharmaceuticals (OTC:CMOPF) has renewed its strategic manufacturing agreement with Takeda (NYSE:TAK) for the production of Mesalazine MMX 1200 mg, marketed as Lialda in the USA and Mezavant in Europe, for ulcerative colitis treatment.
The multi-year agreement will be executed at Cosmo's 18,000 m虏 manufacturing facility in Lainate, Italy, which is ISO 13485 certified and approved by multiple regulatory authorities worldwide. The facility has been supporting global pharmaceutical production for over 30 years.
This renewal aligns with Cosmo's Vision 2030 strategy to expand trusted partnerships and strengthen its Contract Development and Manufacturing Organization (CDMO) leadership globally.
Cosmo Pharmaceuticals (OTC:CMOPF) ha rinnovato il suo accordo strategico di produzione con Takeda (NYSE:TAK) per la realizzazione di Mesalazina MMX 1200 mg, commercializzata come Lialda negli USA e Mezavant in Europa, per il trattamento della colite ulcerosa.
Il contratto pluriennale sar脿 eseguito presso l'impianto produttivo di 18.000 m虏 di Cosmo a Lainate, Italia, certificato ISO 13485 e approvato da numerose autorit脿 regolatorie a livello globale. Questa struttura supporta la produzione farmaceutica mondiale da oltre 30 anni.
Il rinnovo si inserisce nella strategia Vision 2030 di Cosmo, che punta ad ampliare partnership affidabili e a rafforzare la sua leadership come Contract Development and Manufacturing Organization (CDMO) a livello internazionale.
Cosmo Pharmaceuticals (OTC:CMOPF) ha renovado su acuerdo estrat茅gico de fabricaci贸n con Takeda (NYSE:TAK) para la producci贸n de Mesalazina MMX 1200 mg, comercializada como Lialda en EE. UU. y Mezavant en Europa, para el tratamiento de la colitis ulcerosa.
El acuerdo plurianual se llevar谩 a cabo en la planta de fabricaci贸n de 18,000 m虏 de Cosmo en Lainate, Italia, certificada ISO 13485 y aprobada por m煤ltiples autoridades regulatorias a nivel mundial. La instalaci贸n ha apoyado la producci贸n farmac茅utica global durante m谩s de 30 a帽os.
Esta renovaci贸n est谩 alineada con la estrategia Vision 2030 de Cosmo, que busca expandir asociaciones confiables y fortalecer su liderazgo en Contract Development and Manufacturing Organization (CDMO) a nivel global.
Cosmo Pharmaceuticals (OTC:CMOPF)電� 甓れ枒靹� 雽�鞛レ椉 旃橂鞝滌澑 Mesalazine MMX 1200 mg鞚� 氙戈淡鞐愳劀電� Lialda, 鞙犽熃鞐愳劀電� Mezavant霛茧姅 鞚措鞙茧 韺愲Г頃橂姅 Takeda (NYSE:TAK)鞕�鞚� 鞝勲灥鞝� 鞝滌“ 瓿勳暯鞚� 臧膘嫚頄堨姷雼堧嫟.
鞚� 雼る厔 瓿勳暯鞚� ISO 13485 鞚胳鞚� 氚涭晿鞙茧┌ 鞝� 靹戈硠 鞐煬 攴滌牅 旮瓣磤鞚� 鞀轨澑鞚� 須嶋摑頃� 鞚错儓毽晞 霛检澊雮橅厡鞐� 鞙勳箻頃� 18,000 m虏 攴滊鞚� Cosmo 鞝滌“ 鞁滌劋鞐愳劀 歆勴枆霅╇媹雼�. 鞚� 鞁滌劋鞚� 30雲� 鞚挫儊 旮�搿滊矊 鞝滌暯 靸濎偘鞚� 歆�鞗愴暣鞕旍姷雼堧嫟.
鞚措矆 瓿勳暯 臧膘嫚鞚� 鞁犽頃� 靾� 鞛堧姅 韺岉姼雱堨嫮鞚� 頇曤寑頃橁碃 鞝� 靹戈硠鞝侅溂搿� Contract Development and Manufacturing Organization (CDMO) 毽崝鞁潉 臧曧檾頃橂牑電� Cosmo鞚� Vision 2030 鞝勲灥瓿� 鞚检箻頃╇媹雼�.
Cosmo Pharmaceuticals (OTC:CMOPF) a renouvel茅 son accord strat茅gique de fabrication avec Takeda (NYSE:TAK) pour la production de Mesalazine MMX 1200 mg, commercialis茅e sous le nom de Lialda aux 脡tats-Unis et Mezavant en Europe, pour le traitement de la colite ulc茅reuse.
L'accord pluriannuel sera ex茅cut茅 dans l'installation de fabrication de 18 000 m虏 de Cosmo 脿 Lainate, en Italie, certifi茅e ISO 13485 et approuv茅e par plusieurs autorit茅s r茅glementaires 脿 travers le monde. Cette installation soutient la production pharmaceutique mondiale depuis plus de 30 ans.
Ce renouvellement s'inscrit dans la strat茅gie Vision 2030 de Cosmo, visant 脿 茅tendre des partenariats de confiance et 脿 renforcer son leadership en tant qu'Organisation de D茅veloppement et de Fabrication sous Contrat (CDMO) 脿 l'茅chelle mondiale.
Cosmo Pharmaceuticals (OTC:CMOPF) hat seine strategische Fertigungsvereinbarung mit Takeda (NYSE:TAK) f眉r die Herstellung von Mesalazin MMX 1200 mg erneuert, das in den USA als Lialda und in Europa als Mezavant zur Behandlung von Colitis ulcerosa vermarktet wird.
Die mehrj盲hrige Vereinbarung wird in der 18.000 m虏 gro脽en Produktionsst盲tte von Cosmo in Lainate, Italien umgesetzt, die ISO 13485 zertifiziert ist und von mehreren weltweiten Regulierungsbeh枚rden zugelassen wurde. Die Anlage unterst眉tzt seit 眉ber 30 Jahren die globale pharmazeutische Produktion.
Diese Erneuerung steht im Einklang mit Cosmos Vision 2030-Strategie, vertrauensw眉rdige Partnerschaften auszubauen und seine F眉hrungsposition als Contract Development and Manufacturing Organization (CDMO) weltweit zu st盲rken.
- Renewal of strategic manufacturing partnership with major pharmaceutical company Takeda
- Reinforces Cosmo's position as a trusted global manufacturing partner
- Alignment with Vision 2030 strategy for CDMO leadership expansion
- Manufacturing facility has regulatory approvals from multiple global authorities
- None.
Dublin, Ireland--(Newsfile Corp. - August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its multi-year manufacturing and supply agreement with Takeda (TSE: 4502) (NYSE: TAK), to produce Mesalazine MMX 1200 mg (marketed as Lialda® in the USA and as Mezavant in Europe) oral, once-daily treatment for ulcerative colitis, reinforcing its position as a trusted partner for global production of key medicines.
“This renewal underscores our long-standing collaboration with Takeda and our best-in-class manufacturing capabilities,” said Giovanni Di Napoli, CEO of Cosmo. “We are proud of the trust our partners place in our R&D expertise and our ability to deliver high-quality pharmaceutical solutions. This agreement further strengthens our commitment to innovation, sustainability, and excellence, and it aligns perfectly with our Vision 2030 strategy to scale trusted partnerships and grow our CDMO leadership globally.”
Cosmo’s advanced manufacturing site in Lainate (Italy) is approved by multiple regulatory authorities worldwide. It continues to play a key role in supporting global pharmaceutical players, thereby ensuring efficient and environmentally responsible production and excellent supply chain for more than 30 years. The quality system of the 18.000 m² site is certified in accordance with the ISO 13485 standards and is focused on continuous improvement and customer satisfaction.
About Cosmo
Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy).
For more information, visit
Financial calendar
| H.C. Wainwright 27th Annual Global Investment Conference, New York City, USA | September 8-10, 2025 |
For further information, please contact:
Attachments
To view the source version of this press release, please visit
FAQ
What is the new manufacturing agreement between Cosmo Pharmaceuticals (CMOPF) and Takeda?
Where will Cosmo manufacture the ulcerative colitis treatment for Takeda?
How does this agreement align with Cosmo's business strategy?
What certifications does Cosmo's manufacturing facility have?
